These Analysts Increase Their Forecasts On Merit Medical Systems After Strong Q2 Results

Merit Medical Systems Inc (NASDAQ: MMSI ) posted better-than-expected earnings for the second quarter on Thursday.

The company posted adjusted EPS of $1.19, beating market estimates of 96 cents per share.

The company’s sales came in at $418.843 million versus expectations of $405.268 million.

Merit Medical Systems raised its FY2026 adjusted EPS guidance from $4.01-$4.15 to $4.25-$4.35 and increased its sales forecast from $1.612 billion-$1.634 billion to $1.631 billion-$1.643 billion. “Merit delivered second quarter financial results that exceeded the high end of our expectations, driven primarily by 9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture,” said Martha G.

Aronson, Merit’s President and CEO. “We experienced improving revenue growth trends across our global business in Q2, as expected, with notable strength in sales to customers in the U.S. which increased 10% year-over-year, well ahead of our expectations.

We also delivered improvement in both our non-GAAP operating margin and our non-GAAP earnings per share, which increased by 140 basis points and 18%, respectively, year-over-year.” Merit Medical shares gained 4.4% to $87.00 in pre-market trading.

These analysts made changes to their price targets on Merit Medical following earnings announcement.

BTIG analyst Sam Eiber maintained the stock with a Buy and raised the price target from $100 to $105.

Needham analyst Mike Matson maintained the stock with a Buy and raised the price target from $90 to $101.

Considering buying MMSI stock? Here’s what analysts think: Photo via Shutterstock